Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY
Green A, Curtis H, Higgins R, Nab L, Mahalingasivam V, Smith R, Mehrkar A, Inglesby P, Drysdale H, DeVito N, Croker R, Rentsch C, Bhaskaran K, Tazare J, Zheng B, Andrews C, Bacon S, Davy S, Dillingham I, Evans D, Fisher L, Hickman G, Hopcroft L, Hulme W, Massey J, MacDonald O, Morley J, Morton C, Park R, Walker A, Ward T, Wiedemann M, Bates C, Cockburn J, Parry J, Hester F, Harper S, Douglas I, Evans S, Goldacre B, Tomlinson L, MacKenna B. Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY. BMJ Medicine 2023, 2: e000276. PMID: 36936265, PMCID: PMC9951378, DOI: 10.1136/bmjmed-2022-000276.Peer-Reviewed Original ResearchDescriptive cohort studyHigh-risk groupSevere outcomesHigh riskCohort studyHome residentsRisk groupsAntiviral drugsCOVID-19Community settingsMonoclonal antibodiesCasirivimab/imdevimabLow treatment coverageNHS regionProportion of patientsCOVID-19 infectionRoutine clinical dataOpenSAFELY platformUnvaccinated patientsClinical characteristicsLiver diseaseClinical dataTreatment coverageEligibility criteriaPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply